Hunting and Fishing For A Cure Supports the Following ALS Partners: 

Houston Methodist Neurological Institute

The Houston Methodist Neurological Institute is one of the leading neuroscience centers in the nation, offering unparalleled comprehensive care for patients with neurological disorders. Our physicians are among the top specialists in multiple aspects of neurological care. Both general and subspecialty expertise is provided in state-of-the-art facilities. Through the integration of neurological specialities, we are able to provide the utmost in personalized care for complex neurological disorders, from diagnosis to teatment to rehabilitiation. This type of excellence in patient care if at the forefront of all we do and all we strive to achieve.

  • Ranked #11 out of 1,370 hospitals by US News & World Report in 2013; remain top-ranked program for neurology and neurosurgery in TX
  • Research pioneer in ALS, stroke, Parkinson’s disease, Alzheimer’s disease, concussions, brain aneurysms and tumors, epilepsy, Tourette’s Syndrome, and spinal disorders
  • Fully accredited neurology and neurosurgery residency programs in collaboration with Weill Cornell Medical College

Stanley Appel

Stanley H. Appel, M.D. is the Director of the Houston Methodist Neurological Institute, Chair of the Department of Neurology, and the Edwards Distinguished Endowed Chair for ALS at Houston Methodist Hospital in Houston, TX. He is also Professor of Neurology at Weill Cornell Medical College. Dr. Appel received his Bachelor Degree at Harvard University and his Medical Degree from Columbia College of Physicians and Surgeons. Dr. Appel is the author of 15 published books and over 400 articles on topics such as Amyotrophic Lateral Sclerosis (ALS), neuromuscular disease, Alzheimer Disease, and Parkinson Disease. He has received a number of awards for his accomplishments in Neurology and Biochemistry, including the 1997 Gold Medal for Excellence in Biomedical Research from Columbia College of Physicians and Surgeons, the 2003 Sheila Essey Award for ALS Research, 2004 MDA’s Wings Over Wall Street Diamond Award, 2005 Texas Neurological Society Lifetime Achievement Award, 2005 Forbes Norris Award for “compassion and love for humanity in research and treatment in patients with ALS” from the International Alliance of ALS/MND Associations, and the 2008 John P. McGovern Compleat Physician Award. 

MDA/ALS Center at Houston Methodist Neurological Institute

The MDA/ALS clinic at the Houston Methodist Neurological Institute is the first multidisciplinary care center for patients with ALS in the US. Many of our members have practiced together for over 20 years, and we hold ourselves to the highest standards when caring for patients with ALS. Known as “Team Hope”, the clinic’s 21 neuromuscular disease specialists spanning 11 subscpecialties provide comprehensive evaluation and unsurpassed treatment options in an enviroment of compassion and support. A focus on the emotional well-being of ALS patients and their caregivers is a major strength of the clinic. Our center is actively involved in both clinical and basic science research.


About ALS Therapy Development Institute (ALS TDI)

The ALS Therapy Development Institute (ALS TDI) is the world’s largest ALS-dedicated drug development organization. Founded in 1999 by a patient and his family, people living with ALS continue to play a crucial role in the running of the Institute today. More than 86% of each dollar raised is spent directly on the  Institute’s mission: to discover and develop effective treatments to end ALS. For more information, visit

  • 25-30 potential treatments screened each year
  • Over 15 active partnerships around the world
  • Funded by 150+ grassroots initiatives, foundations, grants, bequests
  • Rated 4-stars by

Steve Perrin

Steve Perrin, Ph.D., is the Chief Executive and Scientific Officer of the ALS Therapy Development Institute (ALS TDI), Dr. Perrin leads the team in selecting, screening, and advancing the best potential treatments for ALS into the clinic as well as raising more that $10 million annually to support that effort. Steve is a frequent speaker on how the medical research paradigm can be modified to accelerate drug development, and has been quoted in the Wall Street Journal, Boston Globe, Boston Herald, New York Times, Nature Medicine, and many others.